Cost-Containment as Part of Pharmaceutical Policy

Author： Almarsdóttir Anna   Traulsen Janine  

Publisher： Springer Publishing Company

ISSN： 0928-1231

Source： Pharmacy World and Science, Vol.27, Iss.3, 2005-06, pp. : 144-148

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug price cuts have been made a priority for the French government's pharmaceutical cost-containment policy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 340, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Cost-containment strategies successful in Taiwan

By  

Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996-2003

By Lee Yue-Chune  

PharmacoEconomics, Vol. 24, Iss. 9, 2006-01 ,pp. : 891-902

Adis International

Access to resources Recommend Favorite

Conclusions about Canadian drug cost containment `unwarranted'

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 334, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The cost of pharmaceutical innovation to patients

By Keyhani Salomeh   Ross Joseph S  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 11, 2007-11 ,pp. : 1431-1434

Informa Healthcare

Access to resources Recommend Favorite